SCHEMBL23461111

SCHEMBL23461111

CCC(C)(C)[C@H](NC(=O)c1ccc2ccc(C(F)(F)F)cc2c1OCc1ccc(C(F)(F)F)cc1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 1/20 0.56
▸ MME P08473 2/20 0.41
▸ ACE P12821 2/20 0.41
▸ CPA1 P15085 2/20 0.41
▸ ACE2 Q9BYF1 2/20 0.41
▸ KIFC1 Q9BW19 1/20 0.40
▸ PPARG P37231 4/20 0.39
▸ PPARD Q03181 3/20 0.39
▸ MAOB P27338 3/20 0.38
▸ PPARA Q07869 6/20 0.38
▸ FFAR1 O14842 2/20 0.37
▸ MRGPRX4 Q96LA9 1/20 0.37
▸ RXRA P19793 1/20 0.36
▸ RXRB P28702 1/20 0.36
▸ RXRG P48443 1/20 0.36
▸ PSEN1 P49768 3/20 0.36
▸ PSEN2 P49810 3/20 0.36
▸ APH1B Q8WW43 3/20 0.36
▸ NCSTN Q92542 3/20 0.36
▸ APH1A Q96BI3 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23461113 1.00 CXCR2 (0.56) CXCR2MMEACECPA1ACE2
SCHEMBL23461048 0.94 CXCR2 (0.54) CXCR2MMEACECPA1ACE2
SCHEMBL25548797 0.94 CXCR2 (0.54) CXCR2MMEACECPA1ACE2
SCHEMBL38147169 0.94 CXCR2 (0.54) CXCR2MMEACECPA1ACE2
SCHEMBL23460861 0.94 CXCR2 (0.54) CXCR2MMEACECPA1ACE2
SCHEMBL23460712 0.94 CXCR2 (0.54) CXCR2MMEACECPA1ACE2
SCHEMBL23460713 0.94 CXCR2 (0.54) CXCR2MMEACECPA1ACE2
SCHEMBL23460896 0.94 CXCR2 (0.54) CXCR2MMEACECPA1ACE2
SCHEMBL23460907 0.93 CXCR2 (0.53) CXCR2MMEACECPA1ACE2
SCHEMBL23460910 0.93 CXCR2 (0.53) CXCR2MMEACECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
WO-2021113806-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION (US) 2021-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885MME 1991/4885ACE 2103/4885
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 CXCR2 63/4885MME 2964/4885ACE 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback